A mitochondrial protein called Miro1 accumulates in skeletal muscle in people with type 2 diabetes and may contribute to reduced responsiveness to insulin, according to a study published October 19, 2026, in Nature Communications. The research combined human muscle biopsies, a 12-week randomized exercise intervention, and experiments in mice and muscle cells to investigate how mitochondrial regulation affects glucose uptake.
Miro1 accumulated in muscle from people with type 2 diabetes
Skeletal muscle is a major site of insulin-stimulated glucose disposal. After a meal, insulin signals muscle cells to move glucose transporter 4 (GLUT4) toward the cell surface, allowing circulating glucose to enter cells. This process becomes less efficient in insulin resistance, a central feature of type 2 diabetes.
Elizabeth Heintz and colleagues examined mitochondrial Rho GTPase 1 (Miro1), a protein anchored to the outer membrane of mitochondria. Miro1 has established roles in mitochondrial movement, interactions between organelles, calcium sensing, and mitochondrial quality control. The team asked whether its regulation also affects insulin action in skeletal muscle.
In a cross-sectional human analysis, investigators studied adults classified as healthy weight, obesity without diabetes, or obesity with type 2 diabetes. Participants underwent fasting skeletal-muscle biopsy and a hyperinsulinemic-euglycemic clamp, a research method that measures insulin sensitivity while holding blood glucose near a target level through controlled insulin and glucose infusions.
Miro1 protein abundance was elevated in the muscle of participants with type 2 diabetes, but not in those with obesity alone. Greater Miro1 abundance showed a modest inverse correlation with measured insulin sensitivity, driven largely by the diabetes group. This pattern matters: it does not establish that obesity by itself increases muscle Miro1, nor does a cross-sectional association establish which change came first.
Impaired AKT signaling may allow Miro1 to accumulate on mitochondria
The researchers then examined why Miro1 levels were elevated. In a standard insulin response, the signaling protein AKT helps trigger GLUT4 movement to the muscle-cell membrane. The paper also describes a less familiar part of this signaling pathway: insulin-stimulated AKT can associate with mitochondria, where it interacts with Miro1.
In experimental muscle cells, insulin exposure reduced Miro1 expression. The investigators found evidence that the mitochondrial interaction between AKT and Miro1 was impaired under insulin-resistant conditions. They proposed that disrupted signaling allows excessive Miro1 accumulation, which in turn may worsen mitochondrial organization and glucose regulation.
This creates a potential feedback relationship rather than a simple one-way explanation. Insulin resistance may permit Miro1 buildup, while the buildup may further impair insulin action. The experiments support the proposed pathway, but human biopsy observations alone cannot establish its complete sequence.
Twelve weeks of supervised exercise reduced Miro1 in human muscle
To test whether a treatment already known to improve insulin sensitivity also affected Miro1, the researchers analyzed a parallel-arm, open-label randomized trial registered as NCT02977442. Sedentary adults with obesity and established type 2 diabetes were assigned either to continued standard medical care and lifestyle counseling or to 12 weeks of supervised aerobic exercise.
The exercise program generally consisted of treadmill walking or jogging, or stationary cycling, for approximately 50–60 minutes a session, five days per week. Exercise intensity was progressively increased. Researchers measured fitness, body composition and insulin sensitivity, and obtained skeletal-muscle samples before and after the intervention.
Compared with standard care, exercise improved insulin sensitivity and aerobic capacity and reduced fat mass. Muscle analyses showed less Miro1 accumulation, reduced mitochondrial fragmentation, changes in proteins involved in mitochondrial organization, and improvements in measures of oxidative capacity. The researchers also observed favorable changes in skeletal-muscle lipid droplets and insulin-responsive GLUT4 localization.
Because exercise changes many biological pathways simultaneously, this randomized comparison cannot show that lower Miro1 caused the improvement in insulin sensitivity. It does, however, demonstrate that Miro1 levels respond to a real-world physiological intervention in people with type 2 diabetes.
This result complements other Bites of Bio coverage of diet and exercise in early-onset type 2 diabetes, while addressing a distinct question: how muscle cells respond at the mitochondrial level.
Deleting Miro1 improved glucose handling in mouse muscle and cultured cells
The investigators next used genetically modified mice to isolate the role of Miro1 more directly. They deleted the protein selectively in skeletal muscle and studied metabolic responses, including after 16 weeks of high-fat feeding. Loss of muscle Miro1 improved insulin-stimulated glucose disposal and insulin signaling, and increased movement of GLUT4 to the cell surface.
Mouse muscle without Miro1 also showed greater mitochondrial oxidative phosphorylation capacity. In complementary experiments, researchers reduced Miro1 in cultured mouse muscle cells using gene-silencing tools. These cells took up more glucose, including during insulin exposure, and exhibited higher mitochondrial respiratory capacity. The convergence of mouse and cell experiments strengthens the argument that Miro1 can regulate muscle glucose handling directly rather than acting only as a marker of diabetes.
These studies do not establish that deleting Miro1 throughout a human body would be safe. The protein performs important mitochondrial functions in several tissues, and experimental muscle-specific gene deletion is very different from giving a medicine. Any future drug would need to alter this pathway in the intended tissue without disrupting essential mitochondrial processes elsewhere.
Muscle biology adds another dimension to metabolic risk
The findings also help explain why metabolic health depends on more than total body weight. Our recent analysis of visceral versus subcutaneous fat describes how fat distribution relates to diabetes risk. The Miro1 study examines a different contributor: the ability of skeletal muscle to sense insulin, handle glucose and maintain functional mitochondria.
Body composition, fat distribution and muscle insulin responsiveness can change together, but they are not interchangeable measurements. A person can have similar body mass index to another person yet differ substantially in insulin sensitivity. The study suggests that mitochondrial protein regulation is one component of that variation.
Readers seeking broader context can also review how GLP-1 signaling affects blood sugar and appetite. GLP-1-based medications and the Miro1 mechanism represent different biological approaches, and this study did not directly compare them.
What the evidence cannot yet answer
The human muscle analysis was observational and cross-sectional, so it cannot determine whether elevated Miro1 precedes diabetes or develops as insulin resistance worsens. The exercise intervention lasted 12 weeks, and some mechanistic protein measurements were performed in small subsets of available biopsies. The paper does not establish how broadly these findings apply across ages, clinical backgrounds, or longer treatment periods.
The strongest causal evidence came from mouse models and cultured mouse muscle cells. These experiments directly manipulated Miro1 but cannot demonstrate clinical efficacy or safety in humans. Researchers still need prospective studies to establish whether Miro1 changes before diabetes develops, whether it can predict disease progression, and whether tissue-selective modulation improves health outcomes without unwanted effects.
Several outcomes measured in this investigation, including glucose disposal during a clamp, GLUT4 localization and mitochondrial respiration, are mechanistic endpoints. None is equivalent to demonstrating fewer diabetes complications, heart attacks, kidney outcomes or deaths.
Research funding and disclosures
The study reported support from several National Institutes of Health institutes, including the National Institute of Diabetes and Digestive and Kidney Diseases, National Institute on Aging, National Heart, Lung, and Blood Institute, National Institute of General Medical Sciences, and National Center for Complementary and Integrative Health. The authors declared no competing interests.
The researchers conclude that Miro1 links mitochondrial regulation with insulin action in skeletal muscle and merits investigation as a possible therapeutic target. For now, the actionable human finding is narrower: supervised aerobic training improved insulin sensitivity and altered muscle Miro1 in people with type 2 diabetes. Translating the newly identified molecular pathway into a treatment remains an open question.
References
- Heintz EC, Dantas WS, Taylor AL, et al. Miro1 mediates skeletal muscle insulin resistance in type 2 diabetes. Nature Communications. 2026;17:10702. DOI: 10.1038/s41467-026-77278-6.